Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
Status:
Completed
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
Pegfilgrastim is a long-acting recombinant human granulocyte-colony stimulating factor as
support for chemotherapy, which can be used conveniently.
According to the package inserts in America, Europe, and China, the recommended dose for
pegfilgrastim is 6mg per cycle, while it is recommended at a dose of 3.6mg in Japan. It is
still unclear whether pegfilgrastim 3mg can produce similar efficacy with pegfilgrastim 6mg.
In this trial, the investigators prospectively compared the efficacy and safety of
pegfilgrastim 3mg with 6mg in patients with breast cancer receiving AC regimen, a commonly
used regimen in adjuvant chemotherapy for breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences